Gossamer BioGOSS
About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Employees: 135
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
3% more call options, than puts
Call options by funds: $591K | Put options by funds: $576K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
10.32% less ownership
Funds ownership: 91.53% [Q1] → 81.21% (-10.32%) [Q2]
14% less funds holding
Funds holding: 109 [Q1] → 94 (-15) [Q2]
32% less capital invested
Capital invested by funds: $244M [Q1] → $166M (-$78.2M) [Q2]
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Patrick Trucchio 45% 1-year accuracy 67 / 148 met price target | 1,038%upside $10 | Buy Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 45% 1-year accuracy 67 / 148 met price target | 1,038%upside $10 | Buy Reiterated | 30 Aug 2024 |
Wedbush Laura Chico 56% 1-year accuracy 38 / 68 met price target | 355%upside $4 | Outperform Reiterated | 13 Aug 2024 |